1. Academic Validation
  2. Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure

Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure

  • J Med Chem. 2017 Apr 13;60(7):2908-2929. doi: 10.1021/acs.jmedchem.6b01857.
Dorothee Möller 1 Ashutosh Banerjee 1 Taygun C Uzuneser 2 Marika Skultety 1 Tobias Huth 3 Bianca Plouffe 4 Harald Hübner 1 Christian Alzheimer 3 Kristina Friedland 5 Christian P Müller 2 Michel Bouvier 4 Peter Gmeiner 1
Affiliations

Affiliations

  • 1 Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander University Erlangen-Nürnberg , Schuhstraße 19, 91052 Erlangen, Germany.
  • 2 Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nürnberg , Schwabachanlage 6, 91054 Erlangen, Germany.
  • 3 Institute of Physiology and Pathophysiology, Friedrich-Alexander University Erlangen-Nürnberg , Universitätsstraße 17, 91054 Erlangen, Germany.
  • 4 Institute for Research in Immunology and Cancer (IRIC), Department of Biochemistry and Molecular Medicine, University of Montreal , Québec, Canada H3C 1J4.
  • 5 Department of Chemistry and Pharmacy, Molecular and Clinical Pharmacy, Friedrich-Alexander University Erlangen-Nürnberg , Cauerstraße 4, 91058 Erlangen, Germany.
Abstract

1,4-Disubstituted aromatic piperazines are privileged structural motifs recognized by aminergic G protein-coupled receptors. Connection of a lipophilic moiety to the arylpiperazine core by an appropriate linker represents a promising concept to increase binding affinity and to fine-tune functional properties. In particular, incorporation of a pyrazolo[1,5-a]pyridine heterocyclic appendage led to a series of high-affinity Dopamine Receptor partial agonists. Comprehensive pharmacological characterization involving BRET biosensors, binding studies, electrophysiology, and complementation-based assays revealed compounds favoring activation of G proteins (preferably Go) over β-arrestin recruitment at dopamine D2 receptors. The feasibility to design G protein-biased partial agonists as putative novel therapeutics was demonstrated for the representative 2-methoxyphenylpiperazine 16c, which unequivocally displayed antipsychotic activity in vivo. Moreover, combination of the pyrazolo[1,5-a]pyridine appendage with a 5-hydroxy-N-propyl-2-aminotetraline unit led to balanced or G protein-biased dopaminergic ligands depending on the stereochemistry of the headgroup, illustrating the complex structure-functional selectivity relationships at dopamine D2 receptors.

Figures